Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
Michael C. Heinrich, Jean Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, Hans Gelderblom, John Zalcberg, William M. Reichmann, Kam Sprott, Matthew L. Sherman, Sebastian Bauer, Suzanne George (2025). INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.. , 43(4_suppl), DOI: https://doi.org/10.1200/jco.2025.43.4_suppl.tps848.
Article23 days agoGuidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment
César Serrano, Sebastian Bauer, Jean Yves Blay, Paolo G. Casali, Carlo María Cicala, Angelo Paolo Dei Tos, Antonia Digklia, Hans Gelderblom, Antoine Italiano, Robin L. Jones, Bernd Kasper, Anastasios Kyriazoglou, François Le Loarer, Javier Martín‐Broto, Andrea Napolitano, Piotr Rutkowski, Silvia Stacchiotti, William D. Tap, David J. Thomas, Khin Thway, Claudia Valverde, Winette T.A. van der Graaf, Eva Wardelmann, Judith V.M.G. Bovée (2025). Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment. , 11(12), DOI: https://doi.org/10.1001/jamaoncol.2025.3608.
Article23 days agoINSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
John Zalcberg, Jean Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, William M. Reichmann, Kam Sprott, P. H. Cox, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer, Suzanne George (2024). INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.. , 42(3_suppl), DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.tps767.
Article23 days agoThe INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations
Suzanne George, Jean Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, Hans Gelderblom, John Zalcberg, William M. Reichmann, Kam Sprott, P. H. Cox, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer (2024). The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations. , 20(27), DOI: https://doi.org/10.1080/14796694.2024.2376521.
Article23 days agoNovel trial designs for patients with gastrointestinal stromal tumor
César Serrano, S. Rothschild, Guillermo Villacampa, Michael C. Heinrich, Sally L. George, Jean Yves Blay, Jason K. Sicklick, Gary K. Schwartz, Sameer Rastogi, Robin L. Jones, Piotr Rutkowski, Neeta Somaiah, Vı́ctor Navarro, D. Gareth Evans, Jonathan C. Trent (2024). Novel trial designs for patients with gastrointestinal stromal tumor. , 9(1), DOI: https://doi.org/10.1016/j.esmoop.2023.102218.
Letter23 days ago